VITALIZENCT06290141
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 41 versions: 39 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 133 → 138 locations
- Minor Study sites: 133 to 134
- Notable Eligibility criteria expanded, about 44 words
- Study sites: 135 to 133
- Minor Trial sites expanded: 129 → 135 locationsv38
- Minor Study sites: 128 to 129v36
- Minor Trial sites expanded: 123 → 128 locationsv35
- Minor Site contacts updated at 1 of 123 sitesv34
- Minor Study sites: 122 to 123v33
- Minor Trial sites expanded: 118 → 122 locationsv32
- Minor Trial sites expanded: 115 → 118 locationsv31
- Minor Site details revised at 4 of 115 sitesv30
- Minor Study sites: 113 to 115v29
- Notable Eligibility criteria shortened, about 355 words
- Secondary endpoints revised (21)
- Minor Site details revised at 1 of 113 sitesv27
- Minor Study sites: 112 to 113v26
- Minor Study sites: 111 to 112v25
- Minor Study sites: 108 to 111v23
- Minor Study sites: 107 to 108v22
- Minor Study sites: 105 to 107v21
- Minor Study sites: 100 to 105v20
- Minor Study sites: 94 to 100v19
- Notable Primary completion date: Nov 5, 2025 to Jul 9, 2027
- Study sites: 92 to 94
- Study completion date: Nov 19, 2027 to Jan 12, 2029
- Minor Study sites: 90 to 92v17
- Minor Study sites: 89 to 90
- Study completion date: May 19, 2027 to Nov 19, 2027
- Minor Study sites: 85 to 89v15
- Minor Study sites: 82 to 85v14
- Minor Study sites: 81 to 82v13
- Minor Study sites: 78 to 81v12
- Minor Study sites: 70 to 78v11
Notable Eligibility criteria expanded, about 18 wordsv10 Show 4 more changesShow less
- Primary endpoints revised (2)
- Study sites: 69 to 70
- Interventions: IVIg (Drug), IVIg premedication (Drug), Placebo (Drug), Placebo (Drug), Placebo (Drug), riliprubart (Drug), riliprubart (Drug) to IVIg (Drug), Placebo (Drug), Placebo (Drug), Placebo (Drug), riliprubart (Drug), riliprubart (Drug)
- Secondary endpoints revised (21)
- Minor Study sites: 62 to 69v9
- Minor Study sites: 49 to 62v8
- Minor Study sites: 43 to 49v7
- Minor Study sites: 28 to 43v6
- Minor Study sites: 23 to 28v5
- Minor Study sites: 1 to 23
- Start date changed from estimate of May 31, 2024 to Aug 21, 2024
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 18, 2024 to May 31, 2024
- Study sites: 0 to 1
- Minor Start date: Mar 27, 2024 to Apr 18, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
Riliprubart + Placebo IVIg for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
IVIg (IVIg continuation) + Placebo riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
Drugs: riliprubart, Placebo, IVIg
Sites
138 sites in 24 countries
United States 32, China 17, Spain 10, Germany 9, Japan 9, Brazil 6, Czechia 5, France 5, Italy 5, Portugal 5, Turkey (Türkiye) 5, Canada 4, Hungary 4, Argentina 3, Taiwan 3, United Kingdom 3, Belgium 2, Denmark 2, Greece 2, Mexico 2, Switzerland 2, Israel 1, Norway 1, Sweden 1